Honeywell, the American diversified technology group, has entered into a commercial partnership with AstraZeneca to develop and bring to market next-generation respiratory inhalers that use near-zero global warming potential (GWP) propellants to treat asthma and COPD. The propellant HFO-1234ze in a pMDI containing budesonide, glycopyrronium, formoterol fumarate, on which AstraZeneca recently completed Phase I clinical trials, would be developed in the said collaboration